Translational and Clinical Research Grants for Ataxia-Telangiectasia
Supports rigorous translational and clinical research to develop effective therapies for ataxia-telangiectasia, with a focus on neurological symptoms and direct therapeutic impact.
Funder: Ataxia-Telangiectasia Children's Project
Due Dates: Rolling
Funding Amounts: Up to $75,000/year for 1–2 years; direct costs only, no overhead or indirect costs allowed.
Summary: Supports innovative translational and clinical research targeting treatments or tools for ataxia-telangiectasia, with emphasis on neurological symptoms and direct therapeutic relevance.
Key Information: Grants are for direct costs only; no institutional overhead or indirect costs permitted.
Description
The Ataxia-Telangiectasia Children's Project (A-TCP) offers translational and clinical research grants to accelerate the development of effective therapies for ataxia-telangiectasia (A-T), a rare neurodegenerative disease. The program prioritizes projects that provide clear, actionable outcomes and have direct therapeutic relevance—especially those focused on neurological symptoms, neural circuits, immune health, or lung function. While the primary emphasis is on translational and clinical research, early-stage discovery research may be considered if it directly facilitates new treatments or creates essential tools (e.g., validated biomarkers, gene delivery vectors) for advancing A-T research. Proposals must be original, rigorous, and closely aligned with the urgent needs of the A-T patient community.
